Success Metrics

Active Trials
11(73%)

Phase Distribution

Ph phase_2
6
40%
Ph phase_3
4
27%
Ph phase_1
5
33%

Phase Distribution

5

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
5(33.3%)
Phase 2Efficacy & side effects
6(40.0%)
Phase 3Large-scale testing
4(26.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

11

trials recruiting

Total Trials

15

all time

Status Distribution
Active(14)
Other(1)

Detailed Status

Recruiting11
Not yet recruiting3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
11
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 15 (33.3%)
Phase 26 (40.0%)
Phase 34 (26.7%)

Trials by Status

unknown17%
not_yet_recruiting320%
recruiting1173%

Recent Activity

11 active trials
Showing 5 of 15
recruitingphase_2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

NCT05582499
not_yet_recruitingphase_3

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT07556848
recruitingphase_2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

NCT06649331
not_yet_recruitingphase_2

NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC

NCT07412171
recruitingphase_2

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

NCT07314723
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT05582499Phase 2

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting
NCT07556848Phase 3

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

Not Yet Recruiting
NCT06649331Phase 2

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

Recruiting
NCT07412171Phase 2

NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC

Not Yet Recruiting
NCT07314723Phase 2

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Recruiting
NCT06947226Phase 1

A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors

Not Yet Recruiting
NCT06196736Phase 3

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Recruiting
NCT06823427Phase 2

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
NCT06492005Phase 2

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Recruiting
NCT06692166Phase 3

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

Recruiting
NCT05773937Phase 1

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

Recruiting
NCT06079112Phase 1

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Recruiting
NCT06592326Phase 3

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Recruiting
NCT06551233Phase 1

Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)

Recruiting
NCT05216965Phase 1

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Unknown

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15